SAME Stock Overview
PT Sarana Meditama Metropolitan Tbk engages in the hospital management of EMC Hospital Pulomas in Pulomas, East Jakarta.
Sarana Meditama Metropolitan Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||Rp350.00|
|52 Week High||Rp815.00|
|52 Week Low||Rp306.00|
|1 Month Change||-16.67%|
|3 Month Change||2.94%|
|1 Year Change||-33.33%|
|3 Year Change||-33.33%|
|5 Year Change||-37.72%|
|Change since IPO||284.62%|
Recent News & Updates
|SAME||ID Healthcare||ID Market|
Return vs Industry: SAME underperformed the ID Healthcare industry which returned 12.1% over the past year.
Return vs Market: SAME underperformed the ID Market which returned 12.6% over the past year.
|SAME Average Weekly Movement||7.7%|
|Healthcare Industry Average Movement||5.1%|
|Market Average Movement||6.2%|
|10% most volatile stocks in ID Market||11.9%|
|10% least volatile stocks in ID Market||3.0%|
Stable Share Price: SAME is not significantly more volatile than the rest of ID stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: SAME's weekly volatility (8%) has been stable over the past year.
About the Company
PT Sarana Meditama Metropolitan Tbk engages in the hospital management of EMC Hospital Pulomas in Pulomas, East Jakarta. The company was founded in 1984 and is based in Jakarta, Indonesia. PT Sarana Meditama Metropolitan Tbk is a subsidiary of PT Elang Mahkota Teknologi Tbk.
Sarana Meditama Metropolitan Fundamentals Summary
|SAME fundamental statistics|
Is SAME overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SAME income statement (TTM)|
|Cost of Revenue||Rp805.11b|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||6.80|
|Net Profit Margin||9.01%|
How did SAME perform over the long term?See historical performance and comparison
Is Sarana Meditama Metropolitan undervalued compared to its fair value and its price relative to the market?
Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate SAME's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate SAME's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: SAME is poor value based on its PE Ratio (51.5x) compared to the ID Healthcare industry average (19.8x).
PE vs Market: SAME is poor value based on its PE Ratio (51.5x) compared to the ID market (18.7x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SAME's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SAME is good value based on its PB Ratio (1.6x) compared to the ID Healthcare industry average (1.9x).
How is Sarana Meditama Metropolitan forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sarana Meditama Metropolitan has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Sarana Meditama Metropolitan performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SAME has high quality earnings.
Growing Profit Margin: SAME became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: SAME's earnings have declined by 10.2% per year over the past 5 years.
Accelerating Growth: SAME has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: SAME has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (121.6%).
Return on Equity
High ROE: SAME's Return on Equity (2.7%) is considered low.
How is Sarana Meditama Metropolitan's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: SAME's short term assets (IDR700.9B) exceed its short term liabilities (IDR303.0B).
Long Term Liabilities: SAME's short term assets (IDR700.9B) exceed its long term liabilities (IDR263.4B).
Debt to Equity History and Analysis
Debt Level: SAME has more cash than its total debt.
Reducing Debt: SAME's debt to equity ratio has reduced from 52.4% to 2.6% over the past 5 years.
Debt Coverage: SAME's debt is well covered by operating cash flow (221.3%).
Interest Coverage: SAME's interest payments on its debt are well covered by EBIT (28.6x coverage).
What is Sarana Meditama Metropolitan current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SAME's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SAME's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SAME's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SAME's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: SAME is not paying a notable dividend for the ID market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as SAME has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mr. Jusup Halimi serves as President Director and Chief Executive Officer of PT Sarana Meditama Metropolitan Tbk since 2020. He served as a Manager of Indonesian Operations of Affinity Health Ltd., and was...
Experienced Board: SAME's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 44%.
PT Sarana Meditama Metropolitan Tbk's employee growth, exchange listings and data sources
- Name: PT Sarana Meditama Metropolitan Tbk
- Ticker: SAME
- Exchange: IDX
- Founded: 1984
- Industry: Health Care Facilities
- Sector: Healthcare
- Implied Market Cap: Rp5.995t
- Shares outstanding: 17.13b
- Website: https://www.emc.id
Number of Employees
- PT Sarana Meditama Metropolitan Tbk
- Jalan Pulomas Barat VI No. 20
- Kayu Putih
- Jakarta Raya
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/16 00:00|
|End of Day Share Price||2022/05/13 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.